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ABSTRACT
The androgen receptor (AR) is a member of the
nuclear hormone receptor family of transcription
factors that plays a critical role in regulating expression of genes involved in prostate development and
transformation. Upon hormone binding, the AR
associates with numerous co-regulator proteins
that regulate the activation status of target genes
via flux to the post-translational modification
status of histones and the receptor. Here we
show that the AR interacts with and is directly
methylated by the histone methyltransferase
enzyme SET9. Methylation of the AR on lysine 632
is necessary for enhancing transcriptional activity
of the receptor by facilitating both inter-domain
communication between the N- and C-termini
and recruitment to androgen-target genes. We
also show that SET9 is pro-proliferative and antiapoptotic in prostate cancer cells and demonstrates
up-regulated nuclear expression in prostate cancer
tissue. In all, our date indicate a new mechanism
of AR regulation that may be therapeutically
exploitable for prostate cancer treatment.
INTRODUCTION
The androgen receptor (AR) is a member of the nuclear
hormone receptor superfamily of transcription factors
that transmits androgenic signals derived from the testes,
in the form of testosterone/dihydrotestosterone, to
the regulation of genes involved in prostate growth and
development (1). It is well accepted that the AR plays a

pivotal role in prostate cancer (CaP) development and
remains the primary target for therapeutic intervention
(2). Unfortunately, these treatments are ineffective and
activation of the AR signalling cascade via alternative
pathways results in an incurable castrate-resistant form
of the disease (3). Akin to other members of the nuclear
receptor family, activation of the AR is a multi-step
process initiated by binding to its cognate hormone
androgen in the cytoplasm that promotes AR dimerization, intra-receptor interaction via the N- and C-termini
and nuclear translocation (4). Once in the nucleus, the
receptor binds DNA via a central DNA-binding domain
at speciﬁc androgen response elements (AREs) within
target genes, such as prostate speciﬁc antigen (PSA), and
activates transcription via the concerted action of two
separate domains of the receptor; the activation
function-1 (AF-1) domain, contained within the
N-terminal transactivation domain (TD), and the activation function 2 (AF-2) domain present in the C-terminal
ligand-binding domain (LBD) (4).
Given its pleiotrophic effect and importance in prostate
cell fate, transcriptional activity of the AR is under
extremely tight control and is subject to regulation
at multiple levels. The remodelling of the AR upon
hormone-binding creates an interface for the recruitment
of a host of nuclear co-regulator proteins that are requisites for controlling the transcriptional activation of
androgen-dependent genes (5). Of the many co-regulators
identiﬁed to date, several enzymatic activities have been
characterized that can either enhance or attenuate the
activity of the AR (6,7). For example, histone
acetyltransferase (HAT) and histone deacetylase
(HDAC) enzymes function antagonistically within the
AR signalling cascade to regulate the deposition of the
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activating acetylation mark on speciﬁc histone proteins at
receptor target genes and hence provide a layer of receptor
transcriptional regulation (8,9). Moreover, the ﬁnding
that the HAT proteins TIP60, p300 and PCAF directly
acetylate lysines K630, K632 and K633 of the KLKK
motif located in the hinge region of the receptor to
enhance inherent activity demonstrated a role for direct
post-translational modiﬁcation of the AR in controlling
transcriptional output (9–11).
More recently, histone methylation and the enzymes
that catalyse this reversible modiﬁcation have become a
major focus of epigenetic research (10,11). Our present
view is of a dynamic and intricate mode of transcriptional
control that, via discriminate and reversible methylation
of target lysine residues in histones H3 and H4 by histone
methyltransferase (HMT) and histone demethylase
(HDM) enzymes, works to acutely regulate gene expression (12–14). Although not fully understood, ﬂux to
acetylation and methylation status of speciﬁc lysine
residues of histones H3 and H4 within promoter regions
confers both structural changes to the local chromatin
template and provides distinct binding interfaces that
control the interaction of positive and negative components of the transcriptional machinery; culminating in
ordered regulation of gene expression (15,16). Three
methylation states exist namely, mono-, di and
tri-methylation (me1,2,3) that can be either activating or
repressive to transcription depending on the site of modiﬁcation (17). Speciﬁcally, methylation of lysine residues
4 and 36 in histone H3 (H3K4, H3K36) are associated
with up-regulating gene expression and in the maintenance
of euchromatic domains (18,19), while modiﬁcation of
histone H3 lysine 9 and 27 (H3K9, H3K27) (20–22),
together with histone H4 lysine 20 (H4K20) (23,24), is
generally linked with gene repression and in the formation
of heterochromatic regions. In keeping with this notion,
activation of the AR signalling cascade results in
hypermethylation of histone H3-K4 and demethylation
of H3K9 at targeted promoters, implicating an important
role for both HMT and HDM enzymes in receptor regulation (8,25). Although the HDMs LSD1 (25), JMJD2C
(26) and JHDM2A (27) have been shown to be important
for activation of AR function via concerted removal of the
repressive H3K9me marks, the HMTs responsible for
up-regulating H3K4 methylation and AR activity remain
unknown.
The HMT enzyme SET9 was originally isolated from
a HeLa cell nuclear extract and was shown to up-regulate
transcription by catalysing histone H3-K4 monomethylation in a SET domain-dependent manner and
antagonizing both histone H3-K9 methylation and
promoter association of the NURD deacetylase complex
(28–30). Subsequent studies, however, have suggested that
SET9 is primarily a non-histone protein methyltransferase
catalysing modiﬁcation of several transcriptional regulatory proteins, including p53 (31), TAF10 (32), estrogen
receptor (ER) (33) and the RelA subunit of NFkB (34,35).
Similarity between the KLKK motif of the AR hinge
domain and the lysine-rich sequences targeted by SET9 in
several SET9 substrates suggested a potential involvement
of the methylase in AR methylation and regulation. Here

we show by immunoprecipitation (IP) and chromatin
immunoprecipitation (ChIP) experiments in LNCaP
prostate cancer cells that SET9 interacts with the AR
and associates with the androgen-responsive PSA
promoter in a ligand-dependent manner. Importantly,
using both in vitro and in vivo analyses, we demonstrate
for the ﬁrst time that the AR is directly methylated by
SET9 at lysine K632 within the KLKK motif of the
hinge domain and this modiﬁcation is required for
optimal AR activity in prostate cancer cells. Moreover,
we ﬁnd aberrant SET9 expression in prostate cancer by
immunohistochemical analysis implicating a potential role
of SET9 in cancer progression. In all, our data highlight a
new mode of AR regulation that may be therapeutically
exploitable in the future.

MATERIALS AND METHODS
Plasmids and peptides
The following plasmids have been described previously:
pPSALuc, pMMTVLuc, pCMV-b-gal, pCR3.1-SRC-1,
pFlag-AR (36), pVP16-AR-TD, pM-AR-DBD/LBD
(37), Flag-SET9 and Flag-SET9H297A (gifts from Danny
Reinberg, Howard Hughes Medical Institute) (31).
pFlag-ARK632R was generated using site-directed mutagenesis (QuickchangeTM, Stratagene) using pFlag-AR as
template (primer sequences available on request).
The following AR623–640 peptides encompassing the
KLKK motif were generated: ARWT, ARK630R,
ARK632R and ARK632R/K633R (SynBioSci, CA).
Immunohistochemical analysis
A tissue micro-array (TMA) containing 76 cancer biopsies
and 24 benign biopsies was stained [as described in ref.
(38)] using a monoclonal anti-SET9 antibody (clone
5F2.3; Millipore) at a dilution of 1:500. SET9 expression
was scored blindly by intensity of staining in each biopsy
core as being absent (0), weak (+), moderate (++), or
strong (+++). Slides were scanned using a Scanscope
GL scanner (Aperio) and analysed using SpectrumTM
software (Aperio).
3

H Methylation assay

Approximately 0.5 mg of bacterially puriﬁed His-tagged
AR transactivation domain (AR-TD) (39), DNA-binding
domain/Hinge/ligand-binding domain (AR-DBD/H/
LBD) (40) proteins or the AR623–640 peptides were
incorporated into an in vitro methylation reaction containing 1 mg SET9 (Millipore), 2 mCi 3H S-adenosyl methionine
(GE Healthcare) and HMT reaction buffer [250 mM Tris–
HCl (pH. 9), 2.5 mM DTT, 1 mM PMSF] and incubated at
30 C for 30 min. Proteins were separated by PAGE and
exposed to X-ray ﬁlm as described (36).
Detailed descriptions of all other materials and methods
can be found in the Supplementary Data.
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anti-His antibody indicated that SET9 speciﬁcally interacts with the DBD/H/LBD domains of the receptor
(Figure 1D, lane 4), but not the AR-TD (Figure 1D,
lane 1).

RESULTS
SET9 Interacts with the AR
To address a role for SET9 in the AR signalling cascade
we ﬁrst sought to identify an interaction between SET9
and the receptor. Androgen-dependent LNCaP prostate
cancer cells were cultured in steroid-depleted media for
40-h prior to treatment with or without 10 nM dihydrotestosterone (DHT) for 8-h and subject to IP using an
anti-SET9 antibody. Western analysis of immunoprecipitated material using an anti-AR antibody
demonstrated an interaction between endogenous SET9
and AR that is enhanced in the presence of androgen
(Figure 1A). To conﬁrm the interaction, the reciprocal
IP was performed in AR-null HEK293T cells, grown in
serum-containing media, ectopically expressing AR
together with wild-type SET9 or the methyltransferaseinactive mutant SETH297A. As shown in Figure 1B,
immunoprecipitated AR interacted equally well with
both wild-type and mutant forms of SET9.
To address if the interaction between AR and SET9
was direct, we immunoprecipitated puriﬁed His-tagged
SET9 using an anti-SET9 antibody from a mixture
containing either His-tagged N-terminal transactivation
domain (AR-TD) (40) or His-tagged DNA-binding
domain (DBD)/hinge domain (H)/ligand-binding domain
(LBD) (AR-DBD/H/LBD) (39) fragments of the AR
(Figure 1C) and 10 nM DHT. Western analysis using an

A

The AR is methylated by SET9 in vitro and in vivo
The binding of SET9 to the AR-DBD/H/LBD fragment
that contains the 630KLKK633 motif, a sequence that resembles the SET9-methylation sites of p53 [KSK(me)K]
(31) and ER [RSK(me)K] (33), suggested a potential role
for SET9 in directly methylating the AR. To test this,
puriﬁed AR-TD or AR-DBD/H/LBD proteins were
incorporated into an in vitro methylation assay containing
SET9, 3H-labelled S-adenosyl methionine (3H-SAM) and
10 nM DHT. As shown in Figure 2A, the AR-DBD/H/
LBD fragment was directly and speciﬁcally methylated in
the presence of SET9 (Figure 2A, lane 4), but not the
AR-TD that remained unmodiﬁed (Figure 2A, lane 2),
indicating a positive correlation between SET9-AR interaction and receptor methylation. We also detected SET9
auto-methylation as described in ref. (41).
To assess if the AR is directly methylated in vivo, we
immunoprecipitated endogenous AR from LNCaP cells
treated with or without 10 nM DHT for 6-h followed by
western analysis using an anti-pan-methyl-lysine antibody
(Abcam), as previously used to detect both TAF10 (32)
and RelA methylation (34). In the absence of androgen,
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Figure 1. AR and SET9 interact in vitro and in vivo. (A) LNCaP cells grown in steroid-depleted media and treated with and without 10 nM DHT for
6 h were subject to IP using an anti-SET9 antibody followed by western analysis using an anti-AR antibody. (B) HEK293T cells were transiently
transfected with pFlag-AR and either pFlag-SET9 or pFlag-SET9H297A for 48 h prior to IP using an anti-AR antibody followed by immunoblotting
with anti-AR and -Flag antibodies. (C) Diagrammatic representation of the domains of the androgen receptor showing target lysine sequences of
SET9 and sequence of AR peptide used in 3H methylation assays. (D) In vitro IP between His-tagged SET9 and N- and C-terminal fragments of the
AR using anti-SET9 antibody followed by western analysis using an anti-His antibody.
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AR and either SET9 or SET9H297A for 48 h prior to IP and western analysis as in (B).

we detected a methylated species at 110 kDa, corresponding to the AR, that became more pronounced upon
androgen treatment (Figure 2B, compare lanes 1 and 2),
indicating that the AR is methylated in LNCaP cells that
is enhanced upon activation of the receptor.
To address the question of whether SET9 is involved in
AR methylation in LNCaP cells, we employed short
interfering RNA (siRNA) to reduce cellular SET9 levels
and compared receptor methylation to a non-silencing
siRNA control by IP as described above. As shown in
Figure 2C, we achieved 70% knockdown of SET9 72-h
post-siRNA transfection using SET9 siRNA that resulted
in a marked reduction to endogenous receptor methylation (compare lanes 1 and 2) without affecting AR protein
levels. This experiment was repeated using an additional
anti-methyl-lysine antibody (Abcam) for western analysis
and although detection of the methylated AR species was
less robust than the anti-pan-methyl-lysine antibody used
above, SET9 knockdown attenuated receptor methylation
(Supplementary Figure S1) conﬁrming a role for SET9 in
AR methylation in vivo.
In an effort to establish a role for the methyltransferase
activity of SET9 in AR modiﬁcation, we over-expressed
the AR together with either wild-type SET9 or the

methylase-dead SET9H297A mutant, in HEK293T cells
and assessed receptor methylation by IP. As shown in
Figure 2D, AR methylation is enhanced in the presence
of wild-type SET9, but not the methylase-inactive
SET9H297A mutant, suggesting that the HMT activity of
SET9 is necessary for receptor methylation. The fact that
AR methylation levels are reduced below basal levels in
the presence of SET9H297A suggest a dominant-negative
effect of the mutant over endogenous SET9 (Figure 2D,
compare lanes 1 and 3). In all, these in vitro and in vivo
ﬁndings indicate that SET9 methylates the AR.
Lysine 632 of the AR is methylated by SET9
To delineate the site of SET9-mediated AR methylation
we hypothesised that the 630KLKK633 motif would be the
preferred site of modiﬁcation given the similarity with
other known SET9 target sequences. To this end,
peptides encompassing 623–640 amino acids of the AR
containing individual lysine to arginine substitutions at
lysine 630, 632 and a double substitution of 632/633,
were subject to in vitro methylation and analysed by autoradiography. SET9-mediated methylation of wild-type
and K630R peptides was equivalent to modiﬁcation of
histone H3 indicating lysine 630 is not methylated
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in vitro (Figure 3A, left panel). Importantly, substitution
of K632 almost completely abolished methylation and was
accomplished by the double lysine 632/633 substitution,
indicating that although there is trace methylation of
lysine 633 in this assay system, lysine 632 is the preferred
site for SET9-mediated methylation of the peptide in vitro
(Figure 3A, left panel). To conﬁrm this ﬁnding,
methylated and non-methylated wild-type AR623–640
peptides were subjected to mass spectrometry analysis.
Speciﬁcally, one major site of methylation, in the form
of mono-methylation, was detected within the peptide at
lysine 632 with no modiﬁcation of lysines 630 and 638, and
only very weak methylation at lysine 633 that may an
artefact of the methylation reaction (Figure 3A, right
panel and Supplementary Figure S2). This ﬁnding is consistent with the catalytic mechanism of SET9 for p53 (31),
ER (33) and RelA (34).
To investigate whether lysine 632 of the AR is
methylated speciﬁcally in vivo, HEK293T cells grown in
serum-containing media ectopically expressing Flag-SET9
(F-SET9) and either full-length wild-type Flag-AR or
Flag-ARK632R, in which lysine 632 was replaced with
3H-Methylation

SET9 enhances transcriptional activity of the AR
Given that SET9-mediated methylation up-regulates p53
and ER transcriptional activity (31,33), we hypothesised
that SET9 would also enhance transcription of androgenregulated genes. To this end, we depleted endogenous
SET9 levels in LNCaP cells by siRNA and assessed
hormone-dependent expression of the AR-target genes
PSA and TMPRSS2 by quantitative PCR. LNCaP cells
grown in steroid-depleted media supplemented with or
without 10 nM DHT showed robust reductions in both
androgen-dependent PSA (Figure 4A, upper panel) and
TMPRSS2 (Figure 4A, lower panel) expression
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compared to the non-silencing control indicating a role for
SET9 in co-activation of the AR.
To provide evidence of a role for the histone methylase
activity of SET9 in AR activation, wild-type SET9 and
SET9H297A were ectopically expressed in both LNCaP
and HEK293T cells, grown in serum-containing media,
together with the AR (HEK293T cells only) and an
androgen-responsive MMTV luciferase reporter. As
shown in Figure 4B, wild-type SET9, but not the
methylase-inactive mutant, enhanced AR activity by
2.5-fold in both cell lines indicating that the catalytic
activity of SET9 is required for receptor co-activation.
Similarly, the HMT activity of SET9 up-regulated AR
activity upon the PSA luciferase reporter in HEK293T
cells (Supplementary Figure S3A) as well as upon the
androgen-responsive AREIII reporter in the osteosarcoma cell line U2OS (Supplementary Figure S3B). In all,

A

this data is consistent with a role for SET9 as an AR
co-activator.
To test the requirement of AR methylation at lysine 632
for SET9-mediated receptor co-activation, we examined
the effect of SET9 on the activity of wild-type AR and
the ARK632R mutant in MMTV reporter assays in
HEK293T cells grown in steroid-depleted media. As
expected, 10 nM DHT treatment enhanced AR activity
by 3-fold (Figure 4C, compare lanes 1 and 2) that
was further up-regulated by co-expression of SET9
(Figure 4C, compare lanes 2 and 3). In contrast,
although ARK632R responded to androgen stimulation
similar to the wild-type receptor, ectopic expression
of SET9 failed to stimulate the lysine mutant AR
(Figure 4C, compare lanes 5 and 6) indicating that methylation of AR at lysine 632 is necessary and sufﬁcient for
co-activation by SET9.

B

C

Figure 4. SET9 is an AR co-activator. (A) LNCaP cells grown in steroid-depleted media were transiently transfected with non-silencing (N/S) or
SET9 siRNAs for 66 h prior to treatment with and without 10 nM DHT for 6 h followed by RNA extraction and real-time PCR analysis of PSA and
TMPRSS2 mRNA expression. (B) HEK293T and LNCaP cells were transiently transfected for 48 h with AR (HEK293T cells only) and either SET9
or SET9H297A together with both MMTV-luciferase and b-galactosidase reporters prior to luciferase and b-galactosidase expression analyses.
(C) HEK293T cells were transiently transfected and analysed as in (B) with the inclusion of ARK632R. Data represent average of three independent
repeats ± standard error (A–C).
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stability. To test this further, LNCaP cells transiently
transfected with SET9 siRNA or control were subject to
CHX time-course experiments as above. Endogenous AR
destabilization rates in the SET9-depleted cells were
equivalent to control cells (Figure 5B). Moreover,
overexpression of SET9 or SET9H297A did not affect AR
or ARK632R protein levels (Figures 2D and 3C) conﬁrming
that SET9 does not regulate AR turnover.
Another potential mechanism of SET9 co-activation of
the AR would be to enhance nuclear import of the
hormone-activated receptor. To test this, androgendependent nuclear shuttling of the AR was examined in
LNCaP cells with and without SET9 knockdown. As
shown in Figure 5C, SET9-depletion had no apparent
effect on AR translocation to the nucleus after 6 h DHT
stimulation compared to control cells (N/S). In addition,
we found no difference in kinetics of androgen-induced
nuclear movement of wild-type AR versus ARK632R
indicating that the presence of SET9 or receptor methylation has no effect on cytoplasmic-nuclear shuttling of the
receptor in response to hormone (Figure 5D).

AR methylation enhances inter-domain interaction without
affecting receptor stability or cytoplasmic-nuclear shuttling
Having shown a role for receptor methylation in transcriptional co-activation, we next assessed the impact of methylation on the stability of the receptor. Previous reports
have shown differing effects of SET9-mediated methylation on protein stability; both p53 and ER are stabilized
by SET9 (31,33) while the RelA subunit of NFkB (34) and
DNMT1 (41) are both destabilized. To test our hypothesis
that SET9 affects AR stability and hence up-regulates
transcriptional activity of the receptor, cycloheximide
(CHX) time-course experiments were undertaken in
HEK293 cells over-expressing AR with and without
wild-type or methylase-inactive mutant SET9. As shown
in Figure 5A (left panel), in the absence of ectopic SET9,
AR levels are reduced by 50% after 8 h CHX treatment
in serum-containing media which is in line with our
previous ﬁndings (42). Importantly, expression of SET9
(Figure 5A, middle panel) or SET9H297A (Figure 5A,
right panel), had no additional effect on AR protein
levels indicating that SET9 does not impact on receptor
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Figure 5. SET9 enhances AR N- and C-terminal interaction without affecting receptor stability or nuclear shuttling. (A) HEK293T cells transiently
transfected with empty vector, SET9 or SET9H297A were treated with 1 mM cycloheximide (CHX) for up to 8 h and then subject to western analysis
using anti-AR and anti-a-tubulin antibodies. (B) LNCaP cells transiently transfected with non-silencing (N/S) or SET9 siRNAs were treated with
1 mM CHX and subject to western analysis as in (A). (C) LNCaP cells transiently transfected with N/S or SET9 siRNAs in steroid-depleted media
were treated with and without 10 nM DHT for 6 h prior to nuclear-cytoplasmic extraction and western analysis using anti-AR, -PARP1 and
-GAPDH antibodies. (D) HEK293T cells transiently transfected with AR or ARK632R were subject to the same experimental procedure as in (C)
with the inclusion of an additional 10 nM DHT time-point at 2 h. (E) Mammalian two-hybrid analysis of AR-TD and AR-DBD/H/LBD fragment
interaction in HEK293T cells transiently transfected with either SET9, SET9H297A or SRC-1 and Gal4-luciferase and b-galactosidase reporters. Cells
were treated with and without 10 nM DHT for 24-h prior to harvesting, and luciferase and b-galactosidase analyses. Data represents the average of
three independent experiments performed in quadruplicate ± standard error (asterisk represents statistical signiﬁcance <0.05).
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To further decipher the mechanism of SET9-mediated
co-activation of the AR, we next investigated the effect of
methylation on the N–C terminal interaction of the
receptor. Upon hormone-binding, the AR undergoes a
major allosteric re-organization that promotes the association of a region of the N-terminal TD, containing
FXXLF and WXXLF motifs, with the C-terminal AF-2
domain that is vital for transcriptional activity of the
receptor (43,44). Importantly, several components of the
AR signalling cascade have been shown to regulate AR
inter-domain interaction that correlates with their role as
either co-activators or co-repressors. For example, steroid
receptor co-activator 1 (SRC-1) facilitates N–C terminal
interaction to enhance receptor activity (45), while Rad9
attenuates domain association and hence transcriptional
output of the AR (45). Using luciferase reporter-based
mammalian two-hybrid assays in HEK293T cells (37),
incorporating ectopically expressed Gal4DBD-AR-DBD/
LBD and VP16AD-AR-TD proteins, the effect of wildtype SET9 or SET9H297A on AR inter-domain interaction
was assessed. As expected, treatment of cells with 10 nM
DHT increased interaction between the N- and C-terminal
domains of the AR (Figure 5E, compare lanes 1 and 2)
which was further stimulated by co-expression of
increasing amounts of SRC-1. In the presence of
wild-type SET9, inter-domain interaction of the receptor
was enhanced to levels equivalent to SRC-1 (Figure 5E,
lanes 9–11) without affecting inherent activity of
Gal4DBD-AR-DBD/LBD or VP16AD-AR-TD independently (data not shown). Importantly, no enhancement
of interaction was seen in the presence of the
enzymatically-inactive SET9H297A mutant indicating that
the histone methylase activity of SET9 is important for
facilitating the N–C terminal association of the receptor.
Together, our data indicate that the mechanism of AR
co-activation by SET9 is in part dependent upon regulation of inter-domain communication of the receptor
without affecting cytoplasmic-nuclear shuttling or
stability of the AR.
SET9 associates at the AR-regulated PSA gene and is
important for AR recruitment and mono-methylation of
histone H3K4
Having established a co-activator role for SET9 in
AR-mediated transcription, we next sought to identify if
SET9 was recruited to androgen-regulated genes by ChIP
analysis. LNCaP cells grown in steroid-depleted media
were treated with 10 nM DHT over a time-course of 0–
120 min prior to ChIP analysis using an anti-SET9
antibody or an anti-AR antibody control. As expected,
AR recruitment to the proximal (ARE I) and distal
enhancer (ARE III) regions of the PSA promoter
(illustrated in Figure 6A) was androgen-dependent and
showed a more robust recruitment to the ARE III
region compared to ARE I as described previously (46)
(Supplementary Figure S4). In contrast, we found SET9
associated with similar magnitude to both ARE I and III
regions of the PSA promoter in the absence of androgen
(Figure 6A). After 15 min of hormone treatment, SET9
levels at the PSA promoter rapidly decreased, remained

low at 30 min and then increased gradually between
60 and 120 min of androgen stimulation to levels equivalent to the inactive promoter. This dynamic association–
disassociation proﬁle of SET9 is very similar to that seen
for the binding of SET9 to the IL-8 promoter in response
to TNF-a treatment (34), suggesting a common recruitment mechanism for the HMT. Importantly, SET9 was
not present on the same promoter elements in the AR
null PC3 cell line indicating a dependency on the AR
signalling cascade for promoter binding (Supplementary
Figure S5).
Using a stable doxycycline-inducible SET9 knockdown
LNCaP cell line, in which SET9 levels were routinely
reduced by 80% in response to doxycycline treatment,
without affecting AR protein levels (Figure 6B), we next
addressed the role of SET9 at the PSA promoter. Given
that SET9 is a histone H3K4 mono-methylase (28) and
has been shown to mono-methylate H3K4 at several
NFkB genes (56), we hypothesised that reducing SET9
levels would down-regulate the H3K4me1 mark at the
PSA promoter. As shown in Figure 6C, ChIP analysis
using an anti-mono-methyl histone H3K4 antibody
demonstrated the presence of H3K4me1 marks in the
absence of hormone and after 120 min androgen treatment
at both ARE I and ARE III (Figure 6C and
Supplementary Figure S6A) suggesting a correlation
between association of SET9 at the PSA promoter and
mono-methylation of histone H3K4 marks. Importantly,
in the presence and absence of 120 min androgen stimulation, knockdown of SET9 signiﬁcantly reduced H3K4me1
at ARE III (Figure 6C, compare lanes 1–3 and 2–4) and at
ARE I, albeit not signiﬁcantly (Supplementary Figure
S6A), suggesting a role for SET9 in methylation of
H3K4 at the proximal and enhancer regions of the PSA
promoter. To demonstrate that the reduction in H3K4me1
in response to SET9 knockdown was not global, histones
extracted from LNCaP cells with and without SET9 depletion were subject to western analysis using an
anti-H3K4me1 antibody. Reducing cellular SET9 levels
had no effect on global methylation of histone
H3K4me1 (Figure 6D and Supplementary Figure S7) or
methylation of H3K9 (Figure 6D and Supplementary
Figure S7), indicating a role for SET9 in regulating
speciﬁc foci of histone methylation within chromatin.
We next assessed the effect of depleting SET9 levels on
hormone-dependent AR recruitment to the PSA promoter
by ChIP analysis using an anti-AR antibody. In line with
our ﬁndings in Supplementary Figure S4, AR was recruited to ARE I and III after 120 min 10 nM DHT treatment in the absence of doxycycline treatment (Figure 6E
and Supplementary Figure S6B, compare bars 1 and 2).
Upon
doxycycline-induced
SET9
knockdown,
androgen-dependent recruitment of the receptor to ARE
III
was
signiﬁcantly
decreased
compared
to
non-doxycycline-treated cells indicating a role for SET9
in facilitating activated AR binding to the target
promoter (Figure 6E). AR recruitment to the proximal
ARE I region was also reduced, but not signiﬁcantly
(Supplementary Figure S6B) which may be due to
low-level AR binding to this region compared to the
ARE III. Importantly, repeating the above experiments
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Figure 6. SET9 is recruited to the AR-regulated PSA promoter to methylate histone H3K4 and facilitate AR recruitment. (A) LNCaP cells grown in
steroid-depleted media for 72-h were treated with 10 nM DHT over a time-course of 0–120 min and then subject to ChIP analysis using an anti-SET9
antibody, or non-speciﬁc isotype control, followed by quantitative PCR analysis using primers speciﬁc to the proximal (ARE I) and distal (ARE III)
regions of the PSA promoter. (B) Representative SET9 knockdown and AR levels from the stable doxycycline-inducible SET9 knockdown LNCaP
cell line (LNCaP-SET9K/D) compared to the equivalent non-silencing (N/S) cell line (LNCaP-N/SK/D). (C) ChIP analysis of histone H3K4
mono-methylation (H3K4me1) at ARE III in LNCaP-SET9K/D cells treated with and without doxycycline for 48 h and 10 nM DHT for 0 or
120 min. (D) Representative western analysis of global histone H3K4me1 and H3K9me2 modiﬁcations in LNCaP cells transiently transfected
with 25 and 50 nM N/S or SET9 siRNAs. (E) An anti-AR antibody was used in ChIP analysis as in (B). Data represents three independent
repeats ± standard error (A and E).

with a control cell line that expresses a non-silencing
shRNA in response to doxycycline treatment
demonstrated no impact on H3K4 methylation or AR
recruitment indicating that the effects seen with SET9
depletion are not off-target effects of the shRNA (data
not shown).
The above ﬁndings indicate multiple roles for SET9
during AR-mediated transcription, including promoter
and receptor methylation that are important for AR
folding and recruitment to target genes (as illustrated in
Figure 8, see Discussion section). To conﬁrm the importance of direct AR methylation in the transcriptional
process, we over-expressed wild-type AR or AR632 in
AR negative PC3 cells and assessed endogenous PSA expression by quantitative PCR. As expected, wild-type AR
markedly up-regulated PSA levels [as described in ref. (47)],

while expression of the AR methylation site mutant failed
to enhance gene expression indicating that AR methylation is necessary for receptor function in the context of
chromatinized genes (Supplementary Figure S8).
SET9 is important for androgen-dependent cell
proliferation and demonstrates deregulated expression
in prostate cancer
Given SET9 is important for AR-mediated PSA expression
in LNCaP prostate cancer cells (Figure 4A), we next
sought to investigate the role of SET9 in
androgen-dependent cell proliferation. Transient transfection of an siRNA against SET9 resulted in a 40% reduction in hormone-dependent LNCaP cell growth (Figure
7A) compared to control cells indicating a
pro-proliferative effect of SET9 on the AR signalling
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Figure 7. SET9 regulates LNCaP cell proliferation, apoptosis and is aberrantly expressed in prostate cancer. (A) WST-1 proliferation assays were
conducted in SET9-depleted and non-depleted LNCaP cells grown in steroid-depleted media supplemented with 10 nM DHT for 72 h. Data represents the mean of three independent experiments. (B) LNCaP cells grown in serum-containing media and transiently transfected with non-silencing
(N/S), SET9 and/or p53 siRNAs were treated with and without 0.5 mM doxorubicin for 24-h prior to caspase 3 analysis. Data represents the mean of
three independent repeats ± standard error (asterisk represents statistical signiﬁcance <0.05). (C) Representative SET9 staining of prostate tissue
using an anti-SET9 antibody in immunohistochemistry (left panel) and table summarizing nuclear and stromal staining pattern of SET9 in cancer
and normal tissue (right panel).

cascade. A similar result was achieved using
doxycycline-induced SET9 knockdown in LNCaP cells
(data not shown). Further analysis revealed that the reduction in LNCaP cell number upon SET9 knockdown was, in
part, due to a small, but signiﬁcant increase in apoptosis as
measured by caspase 3 expression (Figure 7B, left panel).
This ﬁnding was unexpected considering SET9-null mouse
embryonic ﬁbroblasts (MEFs) demonstrated reduced
apoptosis in response to the DNA damaging agent doxorubicin which was found to be the result of attenuated p53
activity (48). To test the effect of DNA damage on cell
apoptosis with and without SET9-depletion in our
system, LNCaP cells transiently transfected with either
SET9 or N/S siRNAs were treated with 0.5 mM doxorubicin for 24-hours prior to caspase 3 expression analysis. As
expected, control LNCaP cells showed a robust increase in
apoptosis from 9–40% in the presence of doxorubicin
(Figure 7B, middle panel). Interestingly, doxorubicininduced apoptosis was enhanced signiﬁcantly by SET9
knockdown (Figure 7B, middle panel, compare bars 1
and 2) suggesting that SET9 function in LNCaP cells is
anti-apoptotic as opposed to pro-apoptotic in MEFs (48)
and U2OS cells (Supplementary Figure S9A) [as described
in ref. (31)]. Furthermore, although p53 knockdown had
no effect on doxorubicin-induced LNCaP cells apoptosis,
dual depletion of SET9 and p53 in LNCaP cells abrogated
the effects of SET9 knockdown alone (Figure 7B, right
panel, compare bars 2 and 4 and Supplementary Figure
S9B) indicating that p53 remains functional in the
absence of SET9 to facilitate cell death.

Considering the involvement of SET9 in LNCaP cell
proliferation and apoptosis, SET9, like other AR
co-regulators including TIP60 (49) and hPIRH2 (50),
may be aberrantly expressed in prostate cancer (CaP).
To examine expression in human prostate tumours,
parafﬁn-embedded prostate tissue samples, retrieved by
transurethral resection and incorporated into a tissue
micro-array (TMA), were assayed by immunohistochemistry using an anti-SET9 antibody. Out of 76 cases
of CaP and 24 benign prostate controls, 90.5% of malignant tissue demonstrated nuclear SET9 staining (67/74)
which is in contrast to only 33.3% for the benign prostatic
samples (8/24). Representative images are shown in
Figure 7C. Nuclear SET9 expression was found to be signiﬁcantly up-regulated in the malignant epithelium
compared to benign tissue (Mann–Whitney U-test,
P < 0.0001). SET9 immunoreactivity was localized to the
stromal tissue in 66.6% of benign samples (16/24),
compared to only 4.1% of prostate cancer samples (3/
74) indicating SET9 stromal staining is signiﬁcantly
down-regulated in malignant tissue compared to BPH
samples (Mann–Whitney U-test, P < 0.0001) (Figure 7C,
right panel). There was no correlation demonstrated
between SET9 nuclear immunoreactivity and Gleason
grade (Kruskal–Wallis, P = 0.892), presence of bony
metastases at diagnosis (Mann–Whitney U-test,
P = 0.943) or development of bony metastases subsequent
to diagnosis (Mann–Whitney U-test, P = 0.686). There
was also no correlation between SET9 stromal
immunoreactivity and Gleason grade (Kruskal–Wallis,
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P = 0.767). In all, this data demonstrates that SET9
nuclear expression is up-regulated in epithelial cells and
concurrently down-regulated in stromal cells of prostate
cancer tissue compared to benign prostate tissues.
Furthermore, SET9 was shown to be pro-proliferative
and anti-apoptotic in LNCaP cells suggesting deregulation
of SET9 expression may drive uncontrolled cell growth in
cancer.
DISCUSSION
The expanding repertoire of AR co-regulator proteins
identiﬁed over the past decade has provided an indication
to the mechanistic complexity required for acute transcriptional control of the receptor. Additional layers of regulation have been attributed to various post-translational
modiﬁcations of the AR, including phosphorylation (4),
acetylation (9) and ubiquitylation (42) which control, for
example, transcriptional output and stability of the
receptor. Importantly, deregulated activity of several
co-regulator proteins has been postulated to facilitate
the transition from androgen-dependent CaP to an untreatable castrate-resistant phenotype suggesting future
therapies for prostate malignancy may target components
of the AR transcriptome (5). Our current studies identify
SET9 as a novel AR co-regulator that directly methylates
lysine 632 within the hinge domain of the receptor to
enhance AR-mediated transcription. This activation
signal functions to facilitate both inter-domain communication between the N- and C- termini of the receptor and
AR-promoter association without effecting protein stability or nuclear translocation. That SET9 is proproliferative and anti-apoptotic in LNCaP prostate
cancer cells and is aberrantly expressed in CaP suggest
an important role for SET9 in CaP progression and may
constitute a novel therapeutic target.
SET9 was initially characterized as a histone H3K4
mono-methyltransferase (28). However, its inability to
directly methylate mono- and oligonucleosomes in vitro
suggested a more prevalent role for SET9 in non-histone
protein modiﬁcation (51). Indeed, over the past few years,
several in vivo targets of SET9-mediated methylation have
been identiﬁed, including p53 (31), ER (33), RelA (34,35)
and DNMT1 (41). In all cases, methylation has provided
an additional layer of regulation by controlling transcriptional activity and/or stability of these proteins. We ﬁnd
that SET9 directly methylates the AR predominantly at
lysine 632 in vitro and in vivo. Interaction between AR
and SET9 in LNCaP cells is enhanced by androgen
(Figure 1A) and this correlated with methylation of the
receptor, as detected using a pan-methyl-lysine antibody
(Figure 2B) indicating a positive correlation between the
level of methylation and activation status of the receptor.
Establishing a role for SET9-mediated AR methylation
in vivo was achieved by depleting SET9 levels in LNCaP
cells. Although knockdown was not completely efﬁcient
by SET9 siRNA, AR methylation was markedly reduced
indicating that SET9 is important for receptor modiﬁcation (Figure 2C and Supplementary Figure S1).
Knockdown of other HMT enzymes, including SET8, in

LNCaP cells failed to affect AR methylation (data not
shown) suggesting discriminate receptor modiﬁcation by
SET9 in vivo. This notion was conﬁrmed in HEK293T
cells in which AR methylation was shown to be
up-regulated by ectopic expression of wild-type SET9,
but not the methylase-dead SET9H297A mutant.
Importantly, SET9H297A, acting as a dominant negative,
completely diminished methylation of the AR below basal
levels indicating that SET9 is the sole methyltransferase
for AR modiﬁcation in this cell type.
In vitro interaction of SET9 with an AR fragment encompassing the DBD/H/LBD domains catalysed receptor
methylation that we hypothesised to be within the KLKK
motif of the hinge region due to its similarity with the
KSKK and RSKK motifs of p53 and ER, respectively.
Using a combination of in vitro peptide methylation
assays and mass spectrometry, we showed that lysine
632 was predominantly methylated in favour of lysines
630 and 633 within the KLKK motif and the downstream
lysine 638. Indeed, substitution of lysine 632 in the context
of the 18-mer peptide markedly reduced peptide methylation by SET9 conﬁrming speciﬁcity of SET9 for the single
lysine 632 site. Moreover, lysine 632 was found to be
mono-methylated by SET9 which is consistent with the
catalytic mechanism of the methyltransferase (52).
This ﬁnding is in contrast to a recent study investigating
ER methylation that demonstrated a 21-mer AR peptide
containing the KLKK motif (AR-624–644) was not
methylated in vitro by SET9, while peptides containing
the RSKK (ER) and KSKK (mineralocorticoid receptor)
sequences were modiﬁed. Several in vitro methylation experiments have suggested that the consensus sequence for
SET9 mediated methylation is [R/K][S/T/A]K (where K is
the substrate lysine) and the failure for SET9 to modify
the AR peptide was due to the presence of a leucine
adjacent to the target lysine which reduces the ability for
SET9 to directly modify substrate lysines (52). However,
RelA has recently been identiﬁed as a SET9 methylation
target which does not conform to the consensus sequence;
RYK in the N-terminus (Ea and Baltimore, 2009) and
TMKK in the C-terminus (34), suggesting ﬂexibility to
the catalytic activity of SET9 for substrate modiﬁcation.
Therefore, our data demonstrating AR methylation likely
represents the ability for SET9 to methylate proteins containing moderately or poorly conserved methylation consensus sequences and the differences between our in vitro
experiments and those of Subramanian et al. (33) may be a
reﬂection of variation to experimental procedure.
Using SET9 knockdown and over-expression studies,
we have shown that SET9 is a co-activator for the AR
(Figure 4A and B). Moreover, up-regulation of receptor
activity is dependent upon the HMT activity of SET9 and
the target methylation site lysine 632 within the AR
(Figure 4B and C) suggesting methylation of the
receptor is inherently linked with AR activation. Unlike
p53, ER and RelA, however, the stability of the AR was
not affected by SET9 (Figure 5A and B) nor was there an
impact on nuclear shuttling of the active receptor upon
SET9 knockdown or removal of lysine 632 (Figure 5C
and D). Instead, we found that SET9, but not the
methylase-inactive mutant SET9H297A, facilitated the
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N–C terminal interaction of the receptor (Figure 5E), suggesting for the ﬁrst time a role for methylation in
controlling allosteric changes within a protein. Interdomain communication between the N- and C-termini
of the AR is important for facilitating the full transcriptional activity of the receptor and has recently been shown
to be negatively regulated by a region of the hinge domain
containing residues 629–636 (53), encompassing lysine
632. We speculate that methylation of lysine 632 within
this ‘inhibitory region’ of the hinge domain may overcome
the repressive effect of this short sequence on the N–C
terminal interaction, via an as yet undeﬁned mechanism,
to up-regulate transcriptional activity of the receptor.
Using ChIP analysis, we found SET9 associated with
the proximal and distal regions of the inactive
androgen-regulated PSA promoter; a ﬁnding similar to
that described for SET9 association at the quiescent IL-8
promoter (34). Upon hormone stimulation, we showed a
dynamic dissociation-association proﬁle for SET9 that,
again, resembled the kinetics of SET9 during IL-8 activation. Interestingly, upon SET9 knockdown, we found that
mono-methylation of H3K4 at the distal promoter
element ARE III was signiﬁcantly reduced suggesting
that, contrary to the notion of SET9 as a non-HMT,
SET9 is important for methylating histone H3K4 in the
context of the chromatinized PSA promoter. This ﬁnding
is in-line with a role for SET9 in regulating monomethylation of H3K4 at both MCP-1 and TNF-
promoter elements (54). We also demonstrated reduced
AR recruitment to the distal and proximal regions of the
PSA promoter indicating the importance of SET9 in
facilitating AR association to target genes. Whether this
effect is a result of failure of the AR to mediate the N–C
terminal interaction, a process required for androgendependent expression of PSA (55), or due to a reduction
in the histone marks required for AR recruitment is still
unknown, but is likely to be a contribution by both
SET9-mediated activities. As shown in Figure 8, we speculate that SET9-mediated H3K4 mono-methylation within
the context of the inactive promoter creates a chromatin
landscape primed to respond to AR activation and that
upon androgen binding, direct interaction with SET9 and

receptor methylation facilitates AR folding and recruitment to target genes. Indeed, our data demonstrating
up-regulation of the endogenous PSA gene in PC3 cells
in the presence of ectopically expressed wild-type AR, but
not AR632, implicated a role for direct receptor methylation in regulating receptor activity and this event
combined with the presence of positive-acting methylation
marks at target genes is likely to contribute to powerful
transcriptional activation. Preliminary data have shown
that SET9 depletion up-regulates both repressive H3K9
methylation marks and HDAC1 association at the distal
and proximal PSA promoter elements, suggesting that
SET9 functions to retain androgen-regulated genes in a
state of readiness for transcriptional activation
(Gaughan and Robson, unpublished data).
The AR is a target for numerous post-translational
modiﬁcations, including phosphorylation (56), ubiquitylation (42,57) and acetylation (9,58). Lysines 630, 632 and
633 of the hinge domain are targets for acetylation by the
histone acetyltransferases (HATs) p300, PCAF (58) and
TIP60 (42) which is required for optimal transcriptional
activity of the AR. Our ﬁnding that lysine 632 of the
receptor is methylated and is required for SET9-mediated
co-activation, suggests potential interplay between these
modiﬁcations during transcription of AR target genes.
It might be interesting to establish if methylation
precedes, and is required for, acetylation of the AR, a
process that has been described for p53 (48). Preliminary
data has found that PCAF interaction with the AR is
reduced upon removal of the AR methylation site and
co-operativity between SET9 and PCAF for AR
co-activation is dependent upon the HMT activity of
SET9 suggesting a role for methylation in facilitating
PCAF-AR interaction and subsequent co-activation
by PCAF (Gaughan and Robson, unpublished data).
Additional studies to further dissect interaction between
acetylation and methylation would be greatly facilitated
by antibodies to acetylated and methylated AR; both of
which are currently in production.
In keeping with the role of SET9 as an AR co-activator,
our data demonstrate that SET9 depletion reduces
androgen-dependent growth of AR-expressing LNCaP

Figure 8. Postulated model of SET9-mediated regulation of the AR. Our working model is that SET9 enhances AR activity by methylating the
receptor and histone H3-K4. Step 1: SET9 is present at androgen response elements (AREs) in the absence of active AR to mono-methylate H3-K4.
Step 2: Activation of the AR via dihydrotestosterone (DHT) binding enables interaction of SET9 and the AR followed by methylation of the
receptor on lysine 632 that facilitates inter-domain interaction of the N- and C-termini of the AR. Step 3: Methylated AR associates with target genes
and enhances transcription.
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cells by 40% (Figure 7A) which is similar to other
known AR co-regulators, including hPIRH2 (50). For
the ﬁrst time, SET9 tissue expression has been analysed
by immunohistochemistry. Importantly, our analysis of
prostate tissue demonstrated up-regulated SET9 expression in cancer compared to normal (Figure 7C), suggesting
deregulated activity of the methylase in prostate malignancy. We hypothesise that up-regulated expression of
SET9 in the nucleus of CaP tissue, irrespective of
tumour grade or presence of bone metastasis, enhances
nuclear AR function to drive uncontrolled prostate cell
proliferation. It is possible that SET9 deregulation in
CaP impacts on pathways other than AR signalling,
such as the p53 and NF-kB cascades. Interestingly,
we show that SET9 is anti-apoptotic in LNCaP cells
(Figure 7B) which is in contrast to studies in the osteosarcoma cell line U2OS (31) and MEFs derived from SET9
null animals (48) that demonstrate SET9 is pro-apoptotic
as a consequence of up-regulating the p53 pathway. It is
interesting to speculate that the balance of SET9 activity
in speciﬁc cancer types is tipped towards facilitating the
activity of pro-proliferative factors, such as the AR, at the
expense of the anti-proliferative and pro-apoptotic agents
like p53.
In summary, our data highlight a new mode of transcriptional regulation of the AR that adds methylation to
the list of post-translational modiﬁcations of the receptor.
Investigating interplay between these various modiﬁcations will provide a more comprehensive understanding
of AR control and new therapeutic targets for CaP
therapy.
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